Heat Biologics Inc. is winding down a phase II study of its injectable adenocarcinoma cell vaccine, HS-110 (viagenpumatucel-L), in combination with low-dose cyclophosphamide, to focus instead on the potential benefits of combining the vaccine with Opdivo (nivolumab, Bristol-Myers Squibb Co.) to battle non-small-cell lung cancer (NSCLC).